Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Zhang, Wenxiong; Wei, Yiping; Yu, Dongliang; Xu, Jianjun; Peng, Jinhua

doi:10.1186/s12885-018-4685-y

Table 2 Characteristics of included studies

From: Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

Study		Country	Groups	Patients (n)	Median age (year)	Stage	Treatment line	EGFRmutations	Adenocarcinoma (%)	Design	Quality (score)
2010	Kim [19]	Korea	G vs. E	171/171	58/59	IIIb, IV	2, 3	–	86	RS	7
2010	Hotta [20]	Japan	G vs. E	330/209	68/68	II-IV or recurrent	2, 3	–	76	RS	9
2010	Hong [21]	Keroa	G vs. E	20/17	61/67	IIIb, IV	2, 3	–	75	RS	7
2011	Wu [22]	Taiwan	G vs. E	440/276	67/67	IIIb, IV	1 or later	Partial	85	RS	9
2011	Shin [12]	Keroa	G vs. E	100/82	65/65	III, IV	2	Partial	0	RS	7
2011	Togashi [23]	Japan	G vs. E	85/69	65/68	IIIb, IV	1 or later	Partial	82	RS	8
2011	Fan [14]	Taiwan	G vs. E	715/407	–	IIIb, IV	1 or later	Partial	77	RS	8
2011	Jung [24]	Korea	G vs. E	72/51	55/55	IIIb, IV	1 or later	Partial	59	RS	6
2012	Wu [25]	Taiwan	G vs. E	124/100	–	IIIb, IV	1 or later	Partial	100	RS	8
2012	Kim [26]	Keroa	G vs. E	48/48	59/60	IIIb, IV	2	Partial	91	RCT	4
2012	Suzumura [27]	Japan	G vs. E	232/86	67/66	IIIb, IV	–	Partial	95	RS	8
2013	Yoshida [28]	Japan	G vs. E	107/35	64/67	III, IV or recurrent	1 or later	Partial	84	RS	8
2013	Shao [29]	Taiwan	G vs. E	655/329	61/63	IIIb, IV or recurrent	3	–	80	RS	9
2013	Lee [30]	Korea	G vs. E	11/14	49/58	IV	1 or later	Partial	92	RS	8
2013	Yu [31]	China	G vs. E	16/22	54/52	–	3	Partial	100	RS	8
2014	Lim [32]	Korea	G vs. E	121/121	58/58	IIIb, IV	1 or later	All	98	RS	9
2014	Sato [13]	Japan	G vs. E	213/69	66/66	IIIb, IV or recurrent	–	Partial	86	RS	8
2014	Lin [33]	China	G vs. E	57/24	–	IIIb, IV	1	All	59	RS	7
2014	Ren [34]	China	G vs. E	60/142	59/59	IV	1 or later	Partial	66	RS	8
2014	Li [35]	China	G vs. E	53/97	59/59	IIIb, IV	2	Partial	67	RS	8
2014	Takeda [36]	Japan	G vs. E	57/11	69/69	III, IV or recurrent	1 or later	All	99	RS	6
2015	Otsuka [37]	Japan	G vs. E	35/9	70/62	IIIb, IV	1 or later	All	91	RS	9
2015	Song [38]	China	G vs. E	37/65	75/75	IIIb, IV	2 or later	Partial	83	RS	7
2015	Koo [39]	Korea	G vs. E	166/56	–	IV	1, 2, 3	All	87	RS	7
2016	Ruan [40]	China	G vs. E	63/134	59/60	III, IV	–	All	–	RS	8
2016	Hirano [41]	Japan	G vs. E	10/16	71/71	IB-IV or recurrent	–	All	81	RS	8
2016	Urata [10]	Japan	G vs. E	279/280	68/67	IIIb, IV or recurrent	2, 3	Partial	100	RCT	5
2016	Suh [42]	Korea	G vs. E	146/5	65/65	IIIb, IV	1	All	97	RS	7
2016	Kashima [43]	Japan	G vs. E	52/11	68/68	IV	–	All	–	RS	8
2017	Yang [11]	China	G vs. E	128/128	–	IIIb, IV	1, 2	All	96	RCT	5
2017	Kuan [15]	Taiwan	G vs. E	304/63	65/67	IIIb, IV	1	All	–	RS	8

Abbreviations: G gefitinib, E erlotinib, EGFR epidermal growth factor receptor, RS retrospective study, RCT randomized controlled trial, −: not available

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us